JP6530744B2 - 白内障手術後の炎症における徐放性デキサメタゾンの使用 - Google Patents

白内障手術後の炎症における徐放性デキサメタゾンの使用 Download PDF

Info

Publication number
JP6530744B2
JP6530744B2 JP2016515111A JP2016515111A JP6530744B2 JP 6530744 B2 JP6530744 B2 JP 6530744B2 JP 2016515111 A JP2016515111 A JP 2016515111A JP 2016515111 A JP2016515111 A JP 2016515111A JP 6530744 B2 JP6530744 B2 JP 6530744B2
Authority
JP
Japan
Prior art keywords
dexamethasone
unit dose
formulation
single unit
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016515111A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526039A (ja
JP2016526039A5 (OSRAM
Inventor
ヴァーノン ジー ウォン
ヴァーノン ジー ウォン
ウィリアム エス ホワイト
ウィリアム エス ホワイト
マエ ダブリュー フー
マエ ダブリュー フー
グレン ティー フアン
グレン ティー フアン
ファイーナ カラシナ
ファイーナ カラシナ
Original Assignee
アイコン バイオサイエンス インコーポレイテッド
アイコン バイオサイエンス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイコン バイオサイエンス インコーポレイテッド, アイコン バイオサイエンス インコーポレイテッド filed Critical アイコン バイオサイエンス インコーポレイテッド
Publication of JP2016526039A publication Critical patent/JP2016526039A/ja
Publication of JP2016526039A5 publication Critical patent/JP2016526039A5/ja
Application granted granted Critical
Publication of JP6530744B2 publication Critical patent/JP6530744B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
JP2016515111A 2013-05-24 2014-05-23 白内障手術後の炎症における徐放性デキサメタゾンの使用 Active JP6530744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827091P 2013-05-24 2013-05-24
US61/827,091 2013-05-24
PCT/US2014/039319 WO2014190248A1 (en) 2013-05-24 2014-05-23 Use of sustained release dexamethasone in post-cataract surgery inflammation

Publications (3)

Publication Number Publication Date
JP2016526039A JP2016526039A (ja) 2016-09-01
JP2016526039A5 JP2016526039A5 (OSRAM) 2017-07-06
JP6530744B2 true JP6530744B2 (ja) 2019-06-12

Family

ID=51934201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515111A Active JP6530744B2 (ja) 2013-05-24 2014-05-23 白内障手術後の炎症における徐放性デキサメタゾンの使用

Country Status (9)

Country Link
US (4) US10028965B2 (OSRAM)
EP (2) EP3003318B1 (OSRAM)
JP (1) JP6530744B2 (OSRAM)
KR (1) KR102245354B1 (OSRAM)
CN (2) CN105407896B (OSRAM)
AU (1) AU2014268434B2 (OSRAM)
CA (1) CA2913336C (OSRAM)
ES (1) ES2902951T3 (OSRAM)
WO (1) WO2014190248A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2701773T3 (pl) 2011-04-25 2019-09-30 Icon Bioscience, Inc. Prowadniki dawki do strzykawki iniekcyjnej
EP4566638A3 (en) 2015-05-29 2025-08-27 Allergan, Inc. Implant for treatment of an ocular condition
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
AU2019218870B2 (en) 2018-02-09 2024-05-23 Icon Bioscience, Inc. Systems, kits and methods for loading and delivering a small volume dose from a syringe
WO2020168106A1 (en) 2019-02-13 2020-08-20 Notable Labs, Inc. Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer
IT201900003529A1 (it) * 2019-03-11 2020-09-11 Ntc S R L Riduzione della posologia antibiotica in composizioni antibiotico/antinfiammatorio in associazione tra loro per uso oftalmico
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211793A (en) 1979-03-19 1980-07-08 American Cyanamid Company Triethyl citrate solutions of PGE-type compounds
DE3500103C2 (de) 1985-01-04 1987-01-22 R.P. Scherer GmbH, 6930 Eberbach Pharmazeutische Zubereitung mit einem in Wasser und Verdauungssäften schwer löslichen Wirkstoff
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
EP0666733B1 (en) 1992-11-09 1997-08-13 Quest International B.V. Solubilizing agents
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030216303A1 (en) 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
NZ523385A (en) 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
ITMI20032087A1 (it) 2003-10-27 2005-04-28 Pharmafilm S R L Film autosupportanti per uso farmaceutico ed alimentare.
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP3173072A1 (en) 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
EP2266638A3 (de) 2009-06-25 2014-08-13 Biotronik VI Patent AG Biokorrodierbares Implantat mit einer aktiven Beschichtung
WO2011081712A1 (en) 2009-12-31 2011-07-07 Boston Scientific Scimed, Inc. Cryo activated drug delivery and cutting balloons
PL2701773T3 (pl) * 2011-04-25 2019-09-30 Icon Bioscience, Inc. Prowadniki dawki do strzykawki iniekcyjnej
CA2838646A1 (en) * 2011-06-10 2013-04-25 Ramscor, Inc. Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
PL2717914T3 (pl) * 2011-06-10 2020-05-18 Ramscor, Inc. Formulacje o przedłużonym uwalnianiu do dostarczania białek do oka i sposoby ich wytwarzania
US20160095818A1 (en) 2013-06-03 2016-04-07 Mcneil Ab Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity

Also Published As

Publication number Publication date
JP2016526039A (ja) 2016-09-01
CA2913336C (en) 2020-12-15
ES2902951T3 (es) 2022-03-30
KR20160040471A (ko) 2016-04-14
KR102245354B1 (ko) 2021-04-30
EP3003318B1 (en) 2021-12-22
EP3003318A1 (en) 2016-04-13
US20160120879A1 (en) 2016-05-05
US10159683B2 (en) 2018-12-25
AU2014268434B2 (en) 2018-11-22
EP3003318A4 (en) 2017-01-04
AU2014268434A1 (en) 2015-12-10
US20180303851A1 (en) 2018-10-25
EP4082525A1 (en) 2022-11-02
US20230078906A1 (en) 2023-03-16
US20190105330A1 (en) 2019-04-11
US10028965B2 (en) 2018-07-24
CN105407896A (zh) 2016-03-16
WO2014190248A1 (en) 2014-11-27
CN105407896B (zh) 2019-08-27
CN110339153A (zh) 2019-10-18
CA2913336A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
JP6530744B2 (ja) 白内障手術後の炎症における徐放性デキサメタゾンの使用
JP7362870B2 (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
US11684570B2 (en) Pharmaceutical ophthalmic compositions
US20210038592A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160243031A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20160175323A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150129457A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150025511A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
AU2017260327B2 (en) Pharmaceutical Ophthalmic compositions and methods for fabricating thereof
US20190105320A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20190111045A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
HK40008204A (en) Dexamethasone unit dosage form, kit and use for post-cataract surgery inflammation
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
US20160045432A1 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190320

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190517

R150 Certificate of patent or registration of utility model

Ref document number: 6530744

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250